Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Corbus Pharmaceuticals Holdings, Inc.CRBP · Entity 6261 | Director | May 20, 2020 | May 22, 2020 |
| Motus GI Holdings, Inc.MOTS · Entity 93100 | Director · Chairman of the Board | February 10, 2022 | February 11, 2022 |
| NAKED BRAND GROUP INC.NAKD · Entity 166704 | Director · 10% owner | January 12, 2017 | March 15, 2017 |
| Orchestra BioMed Holdings, Inc.OBIO · Entity 434 | Director · See Remarks | September 10, 2026 | September 11, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Corbus Pharmaceuticals Holdings, Inc.
Report date May 20, 2020 · Filed May 22, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option(right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.30 · Expires 2030-05-20 | Direct | 40,500 |
Reported balance
After 2020-05-20 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2020-05-20 · Grant · Acquired 40,500 · Balance 40,500 F1: The option award was made in accordance with the terms of the issuer's 2014 Equity Compensation Plan. The option will vest in equal monthly installments over the course of 12 months beginning on the date of grant. |
Filing footnotes · ownership attribution and instrument terms
F1: The option award was made in accordance with the terms of the issuer's 2014 Equity Compensation Plan. The option will vest in equal monthly installments over the course of 12 months beginning on the date of grant.
Motus GI Holdings, Inc.
Report date February 10, 2022 · Filed February 11, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.46 · Expires 2032-02-10 | Direct | 50,000 |
Reported balance
After 2022-02-10 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-02-10 · Grant · Acquired 50,000 · Balance 50,000 F1: The option award was made in accordance with the terms of the Issuer's 2016 Equity Incentive Plan (the "2016 Plan"). The option becomes exercisable as to 100% of the shares on February 10, 2023. The exercise price is based on the closing price for the shares of the Common Stock on the date of grant in accordance with the terms of the 2016 Plan. |
Filing footnotes · ownership attribution and instrument terms
F1: The option award was made in accordance with the terms of the Issuer's 2016 Equity Incentive Plan (the "2016 Plan"). The option becomes exercisable as to 100% of the shares on February 10, 2023. The exercise price is based on the closing price for the shares of the Common Stock on the date of grant in accordance with the terms of the 2016 Plan.
NAKED BRAND GROUP INC.
Report date January 12, 2017 · Filed March 15, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.14 · Expires 2021-03-13 | IndirectBy Carole S. Hochman Trust | 1,200,000 |
Reported balance
After 2017-03-13 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2017-03-13 · Grant · Acquired 1,200,000 · Balance 1,200,000 F1: The reporting person and an immediate family member are beneficiaries of the Carole S. Hochman Trust. The reporting person is also one of two trustees of the Carole S. Hochman Trust. |
Filing footnotes · ownership attribution and instrument terms
F1: The reporting person and an immediate family member are beneficiaries of the Carole S. Hochman Trust. The reporting person is also one of two trustees of the Carole S. Hochman Trust.
Orchestra BioMed Holdings, Inc.
Report date September 10, 2026 · Filed September 11, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, par value $0.0001 per share ("Common Stock")SEC Table I · non-derivative | Direct | 1,067,463 |
Reported balance
After 2026-09-10 transaction · row 1
1 source rowRow 1 · 2026-09-10 · Tax withholding · Disposed 3,283 · Balance 1,067,463 F1: Represents the withholding of shares by the Issuer to satisfy tax withholding obligations in connection with vesting of restricted stock units ("RSUs"). No shares were sold in the market as a result of the vesting of these RSUs and the satisfaction of tax withholding obligations. |
| Common StockSEC Table I · non-derivative | IndirectBy the DPH 2008 Trust | 432,916 |
Reported balance
After 2026-09-10 transaction · row 2
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 2 · 2026-09-10 · Tax withholding · Disposed 3,283 · Balance 432,916 F1: Represents the withholding of shares by the Issuer to satisfy tax withholding obligations in connection with vesting of restricted stock units ("RSUs"). No shares were sold in the market as a result of the vesting of these RSUs and the satisfaction of tax withholding obligations. |
| Common StockSEC Table I · non-derivative | IndirectBy the Solomon Ascher Hochman 2019 Trust | 2,000 |
Reported balance
Holding disclosure · report date 2026-09-10 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 2,000 |
| Common StockSEC Table I · non-derivative | IndirectBy the Hannah Hochman 2019 Trust | 2,000 |
Reported balance
Holding disclosure · report date 2026-09-10 · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · Balance 2,000 |
| Common StockSEC Table I · non-derivative | IndirectBy the Judah Herman Hochman 2019 Trust | 2,000 |
Reported balance
Holding disclosure · report date 2026-09-10 · row 5
Holding and transaction disclosures are not merged.
1 source rowRow 5 · Balance 2,000 |
| Common StockSEC Table I · non-derivative | IndirectBy the NSH 2008 Family Trust | 3,140 |
Reported balance
Holding disclosure · report date 2026-09-10 · row 6
Holding and transaction disclosures are not merged.
1 source rowRow 6 · Balance 3,140 |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the withholding of shares by the Issuer to satisfy tax withholding obligations in connection with vesting of restricted stock units ("RSUs"). No shares were sold in the market as a result of the vesting of these RSUs and the satisfaction of tax withholding obligations.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 10, 2026 Filed Sep 11, 2026 22:11 UTC | Orchestra BioMed Holdings, Inc. OBIO · Entity 434 | Tax withholdingCommon Stock | 3,283 | $5.81 | $19,074.23 |
DisclosureSEC source: 0001104659-26-107143 · tm2625275-1_4seq1.xml · nonDerivative · entry 2 Hochman David P · CIK 0001292834 · Director · See Remarks 10b5-1 filing: No plan indicated Ownership: Indirect · By the DPH 2008 Trust Disclosed balance after: 432,916 F1 · kind: Represents the withholding of shares by the Issuer to satisfy tax withholding obligations in connection with vesting of restricted stock units ("RSUs"). No shares were sold in the market as a result of the vesting of these RSUs and the satisfaction of tax withholding obligations. Read SEC document |
| September 10, 2026 Filed Sep 11, 2026 22:11 UTC | Orchestra BioMed Holdings, Inc. OBIO · Entity 434 | Tax withholdingCommon Stock, par value $0.0001 per share ("Common Stock") | 3,283 | $5.81 | $19,074.23 |
DisclosureSEC source: 0001104659-26-107143 · tm2625275-1_4seq1.xml · nonDerivative · entry 1 Hochman David P · CIK 0001292834 · Director · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,067,463 F1 · kind: Represents the withholding of shares by the Issuer to satisfy tax withholding obligations in connection with vesting of restricted stock units ("RSUs"). No shares were sold in the market as a result of the vesting of these RSUs and the satisfaction of tax withholding obligations. Read SEC document |
| September 03, 2026 Filed Sep 8, 2026 12:15 UTC | Orchestra BioMed Holdings, Inc. OBIO · Entity 434 | PurchaseCommon Stock, par value $0.0001 per share ("Common Stock") | 10,000 | $4.79 | $47,900.00 |
DisclosureSEC source: 0001104659-26-105690 · tm2624891-1_4seq1.xml · nonDerivative · entry 1 Hochman David P · CIK 0001292834 · Director · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,070,746 F1 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.73 to $4.79. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document |
| June 10, 2026 Filed Jun 12, 2026 20:15 UTC | Orchestra BioMed Holdings, Inc. OBIO · Entity 434 | Tax withholdingCommon Stock | 3,283 | $4.02 | $13,197.66 |
DisclosureSEC source: 0001104659-26-073468 · tm2617747-1_4seq1.xml · nonDerivative · entry 2 Hochman David P · CIK 0001292834 · Director · See Remarks 10b5-1 filing: No plan indicated Ownership: Indirect · By the DPH 2008 Trust Disclosed balance after: 436,199 F1 · kind: Represents the withholding of shares by the Issuer to satisfy tax withholding obligations in connection with vesting of restricted stock units ("RSUs"). No shares were sold in the market as a result of the vesting of these RSUs and the satisfaction of tax withholding obligations. Read SEC document |
| June 10, 2026 Filed Jun 12, 2026 20:15 UTC | Orchestra BioMed Holdings, Inc. OBIO · Entity 434 | Tax withholdingCommon Stock, par value $0.0001 per share ("Common Stock") | 3,283 | $4.02 | $13,197.66 |
DisclosureSEC source: 0001104659-26-073468 · tm2617747-1_4seq1.xml · nonDerivative · entry 1 Hochman David P · CIK 0001292834 · Director · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,060,746 F1 · kind: Represents the withholding of shares by the Issuer to satisfy tax withholding obligations in connection with vesting of restricted stock units ("RSUs"). No shares were sold in the market as a result of the vesting of these RSUs and the satisfaction of tax withholding obligations. Read SEC document |
| June 01, 2026 Filed Jun 2, 2026 20:28 UTC | Orchestra BioMed Holdings, Inc. OBIO · Entity 434 | PurchaseCommon Stock, par value $0.0001 per share ("Common Stock") | 5,000 | $3.83 | $19,150.00 |
DisclosureSEC source: 0001104659-26-069510 · tm2616712-2_4seq1.xml · nonDerivative · entry 1 Hochman David P · CIK 0001292834 · Director · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,064,029 F1 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.80 to $3.91. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document |
| May 15, 2026 Filed May 19, 2026 12:00 UTC | Orchestra BioMed Holdings, Inc. OBIO · Entity 434 | PurchaseCommon Stock, par value $0.0001 per share ("Common Stock") | 5,000 | $3.77 | $18,850.00 |
DisclosureSEC source: 0001104659-26-063510 · tm2614983-2_4seq1.xml · nonDerivative · entry 1 Hochman David P · CIK 0001292834 · Director · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,059,029 F1 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.75 to $3.79. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document |
| March 25, 2026 Filed Mar 27, 2026 20:30 UTC | Orchestra BioMed Holdings, Inc. OBIO · Entity 434 | Tax withholdingCommon Stock, par value $0.0001 per share ("Common Stock") | 32,438 | $4.57 | $148,241.66 |
DisclosureSEC source: 0001104659-26-036162 · tm269936-1_4seq1.xml · nonDerivative · entry 1 Hochman David P · CIK 0001292834 · Director · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,054,029 F1 · kind: Represents the withholding of shares by the Issuer to satisfy tax withholding obligations in connection with vesting of restricted stock units ("RSUs"). No shares were sold in the market as a result of the vesting of these RSUs and the satisfaction of tax withholding obligations. Read SEC document |
| March 13, 2026 Filed Mar 16, 2026 20:54 UTC | Orchestra BioMed Holdings, Inc. OBIO · Entity 434 | PurchaseCommon Stock, par value $0.0001 per share ("Common Stock") | 10,000 | $4.29 | $42,900.00 |
DisclosureSEC source: 0001104659-26-028554 · tm268956-1_4seq1.xml · nonDerivative · entry 1 Hochman David P · CIK 0001292834 · Director · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,086,467 F1 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.28 to $4.30. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document |
| February 12, 2026 Filed Feb 13, 2026 22:00 UTC | Orchestra BioMed Holdings, Inc. OBIO · Entity 434 | GrantCommon Stock, par value $0.0001 per share ("Common Stock") | 504,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-26-015318 · tm266316-1_4seq1.xml · nonDerivative · entry 1 Hochman David P · CIK 0001292834 · Director · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,076,467 F1 · shares: Represents an award of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of Common Stock. The RSUs vest over a three-year period as follows: (i) 25% of the shares will vest 18 months after February 12, 2026 (the "Issue Date"), (ii) 25% of the shares will vest 24 months after the Issue Date, (iii) 25% of the shares will vest 30 months after the Issue Date and (iv) 25% of the shares will vest 36 months after the Issue Date, subject to the Reporting Person's continuous service through such dates. Read SEC document |
| December 10, 2025 Filed Dec 12, 2025 21:15 UTC | Orchestra BioMed Holdings, Inc. OBIO · Entity 434 | Tax withholdingCommon Stock | 3,283 | $4.67 | $15,331.61 |
DisclosureSEC source: 0001104659-25-120659 · tm2533361-1_4seq1.xml · nonDerivative · entry 2 Hochman David P · CIK 0001292834 · Director · See Remarks 10b5-1 filing: No plan indicated Ownership: Indirect · By the DPH 2008 Trust Disclosed balance after: 439,482 F1 · kind: Represents the withholding of shares by the Issuer to satisfy tax withholding obligations in connection with vesting of restricted stock units. No shares were sold in the market as a result of the vesting of these restricted stock units and the satisfaction of tax withholding obligations. Read SEC document |
| December 10, 2025 Filed Dec 12, 2025 21:15 UTC | Orchestra BioMed Holdings, Inc. OBIO · Entity 434 | Tax withholdingCommon Stock, par value $0.0001 per share ("Common Stock") | 40,355 | $4.67 | $188,457.85 |
DisclosureSEC source: 0001104659-25-120659 · tm2533361-1_4seq1.xml · nonDerivative · entry 1 Hochman David P · CIK 0001292834 · Director · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 572,467 F1 · kind: Represents the withholding of shares by the Issuer to satisfy tax withholding obligations in connection with vesting of restricted stock units. No shares were sold in the market as a result of the vesting of these restricted stock units and the satisfaction of tax withholding obligations. Read SEC document |
| November 14, 2025 Filed Nov 17, 2025 22:00 UTC | Orchestra BioMed Holdings, Inc. OBIO · Entity 434 | PurchaseCommon Stock, par value $0.0001 per share ("Common Stock") | 5,000 | $4.07 | $20,350.00 |
DisclosureSEC source: 0001104659-25-113235 · tm2531478-1_4seq1.xml · nonDerivative · entry 1 Hochman David P · CIK 0001292834 · Director · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 612,822 F1 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.06 to $4.10. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document |
| November 13, 2025 Filed Nov 14, 2025 22:00 UTC | Orchestra BioMed Holdings, Inc. OBIO · Entity 434 | Tax withholdingCommon Stock | 3,283 | $4.18 | $13,722.94 |
DisclosureSEC source: 0001104659-25-112699 · tm2531368-1_4seq1.xml · nonDerivative · entry 2 Hochman David P · CIK 0001292834 · Director · See Remarks 10b5-1 filing: No plan indicated Ownership: Indirect · By the DPH 2008 Trust Disclosed balance after: 442,765 F1 · kind: Represents the withholding of shares by the Issuer to satisfy tax withholding obligations in connection with vesting of restricted stock units. No shares were sold in the market as a result of the vesting of these restricted stock units and the satisfaction of tax withholding obligations. Read SEC document |
| November 13, 2025 Filed Nov 14, 2025 22:00 UTC | Orchestra BioMed Holdings, Inc. OBIO · Entity 434 | Tax withholdingCommon Stock, par value $0.0001 per share ("Common Stock") | 3,283 | $4.18 | $13,722.94 |
DisclosureSEC source: 0001104659-25-112699 · tm2531368-1_4seq1.xml · nonDerivative · entry 1 Hochman David P · CIK 0001292834 · Director · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 607,822 F1 · kind: Represents the withholding of shares by the Issuer to satisfy tax withholding obligations in connection with vesting of restricted stock units. No shares were sold in the market as a result of the vesting of these restricted stock units and the satisfaction of tax withholding obligations. Read SEC document |
| September 17, 2025 Filed Sep 19, 2025 21:30 UTC | Orchestra BioMed Holdings, Inc. OBIO · Entity 434 | Tax withholdingCommon Stock | 3,283 | $2.46 | $8,076.18 |
DisclosureSEC source: 0001104659-25-091742 · tm2526559-1_4seq1.xml · nonDerivative · entry 2 Hochman David P · CIK 0001292834 · Director · See Remarks 10b5-1 filing: No plan indicated Ownership: Indirect · By the DPH 2008 Trust Disclosed balance after: 446,048 F1 · kind: Represents the withholding of shares by the Issuer to satisfy tax withholding obligations in connection with vesting of restricted stock units. No shares were sold in the market as a result of the vesting of these restricted stock units and the satisfaction of tax withholding obligations. Read SEC document |
| September 17, 2025 Filed Sep 19, 2025 21:30 UTC | Orchestra BioMed Holdings, Inc. OBIO · Entity 434 | Tax withholdingCommon Stock, par value $0.0001 per share ("Common Stock") | 40,355 | $2.46 | $99,273.30 |
DisclosureSEC source: 0001104659-25-091742 · tm2526559-1_4seq1.xml · nonDerivative · entry 1 Hochman David P · CIK 0001292834 · Director · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 611,105 F1 · kind: Represents the withholding of shares by the Issuer to satisfy tax withholding obligations in connection with vesting of restricted stock units. No shares were sold in the market as a result of the vesting of these restricted stock units and the satisfaction of tax withholding obligations. Read SEC document |
| August 21, 2025 Filed Aug 25, 2025 23:03 UTC | Orchestra BioMed Holdings, Inc. OBIO · Entity 434 | PurchaseCommon Stock, par value $0.0001 per share ("Common Stock") | 6,000 | $2.49 | $14,940.00 |
DisclosureSEC source: 0001104659-25-082635 · tm2524324-2_4seq1.xml · nonDerivative · entry 1 Hochman David P · CIK 0001292834 · Director · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 651,460 F1 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.49 to $2.50. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document |
| August 07, 2025 Filed Aug 8, 2025 23:11 UTC | Orchestra BioMed Holdings, Inc. OBIO · Entity 434 | GrantCommon Stock | 100,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-075782 · tm2523004-3_4seq1.xml · nonDerivative · entry 2 Hochman David P · CIK 0001292834 · Director · See Remarks 10b5-1 filing: No plan indicated Ownership: Indirect · By the DPH 2008 Trust Disclosed balance after: 449,331 F1 · shares: Represents an award of restricted stock units ("RSUs") to the Reporting Person on August 7, 2025 (the "Grant Date"). Each RSU represents a contingent right to receive one share of Common Stock. The RSUs vest over a three-year period as follows: (i) 33.33% of the shares will vest 24 months after the Grant Date, (ii) 33.33% of the shares will vest 30 months after the Grant Date, and (iii) 33.34% of the shares will vest 36 months after the Grant Date, subject to the Reporting Person's continuous service through such dates. Read SEC document |
| August 07, 2025 Filed Aug 8, 2025 23:11 UTC | Orchestra BioMed Holdings, Inc. OBIO · Entity 434 | GrantCommon Stock, par value $0.0001 per share ("Common Stock") | 100,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-075782 · tm2523004-3_4seq1.xml · nonDerivative · entry 1 Hochman David P · CIK 0001292834 · Director · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 645,460 F1 · shares: Represents an award of restricted stock units ("RSUs") to the Reporting Person on August 7, 2025 (the "Grant Date"). Each RSU represents a contingent right to receive one share of Common Stock. The RSUs vest over a three-year period as follows: (i) 33.33% of the shares will vest 24 months after the Grant Date, (ii) 33.33% of the shares will vest 30 months after the Grant Date, and (iii) 33.34% of the shares will vest 36 months after the Grant Date, subject to the Reporting Person's continuous service through such dates. Read SEC document |
| August 04, 2025 Filed Aug 4, 2025 22:16 UTC | Orchestra BioMed Holdings, Inc. OBIO · Entity 434 | PurchaseCommon Stock, par value $0.0001 per share ("Common Stock") | 20,000 | $2.75 | $55,000.00 |
DisclosureSEC source: 0001104659-25-073743 · tm2522548-1_4seq1.xml · nonDerivative · entry 1 Hochman David P · CIK 0001292834 · Director · See Remarks 10b5-1 filing: No plan indicated Ownership: Indirect · By the DPH 2008 Trust Disclosed balance after: 349,331 F1 · price: These shares were purchased in an underwritten public offering of the Issuer at the public offering price of $2.75 per share. Read SEC document |
| June 11, 2025 Filed Jun 13, 2025 20:41 UTC | Orchestra BioMed Holdings, Inc. OBIO · Entity 434 | Tax withholdingCommon Stock | 5,671 | $3.14 | $17,806.94 |
DisclosureSEC source: 0001104659-25-059416 · tm2517997-1_4seq1.xml · nonDerivative · entry 2 Hochman David P · CIK 0001292834 · Director · See Remarks 10b5-1 filing: No plan indicated Ownership: Indirect · By the DPH 2008 Trust Disclosed balance after: 329,331 F1 · kind: Represents the withholding of shares by the Issuer to satisfy tax withholding obligations in connection with vesting of restricted stock units. No shares were sold in the market as a result of the vesting of these restricted stock units and the satisfaction of tax withholding obligations. Read SEC document |
| June 11, 2025 Filed Jun 13, 2025 20:41 UTC | Orchestra BioMed Holdings, Inc. OBIO · Entity 434 | Tax withholdingCommon Stock, par value $0.0001 per share ("Common Stock") | 34,038 | $3.14 | $106,879.32 |
DisclosureSEC source: 0001104659-25-059416 · tm2517997-1_4seq1.xml · nonDerivative · entry 1 Hochman David P · CIK 0001292834 · Director · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 545,460 F1 · kind: Represents the withholding of shares by the Issuer to satisfy tax withholding obligations in connection with vesting of restricted stock units. No shares were sold in the market as a result of the vesting of these restricted stock units and the satisfaction of tax withholding obligations. Read SEC document |
| April 04, 2025 Filed Apr 5, 2025 01:44 UTC | Orchestra BioMed Holdings, Inc. OBIO · Entity 434 | GrantStock Option (Right to Buy) · Derivative | 147,500 | $0.00 Strike: $2.76 | $0.00 |
DisclosureSEC source: 0001104659-25-032334 · tm2511637-3_4seq1.xml · derivative · entry 7 Hochman David P · CIK 0001292834 · Director · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 147,500 Underlying: Common Stock · 147,500 shares Expires 2035-04-04 F2 · derivative.exercise_date: The stock options will vest as follows: (i) 36,875 of the stock options will vest on April 4, 2026 (the "Vesting Commencement Date") and (ii) the remaining 110,625 stock options will vest in equal installments every three months on the same day of the month as the Vesting Commencement Date, starting on July 4, 2026, subject to the Reporting Person's continuous service through such dates. Read SEC document |
| April 04, 2025 Filed Apr 5, 2025 01:44 UTC | Orchestra BioMed Holdings, Inc. OBIO · Entity 434 | GrantCommon Stock, par value $0.0001 per share ("Common Stock") | 98,333 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-032334 · tm2511637-3_4seq1.xml · nonDerivative · entry 1 Hochman David P · CIK 0001292834 · Director · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 579,498 F1 · shares: Represents an award of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of Common Stock. The RSUs vest over a three-year period as follows: (i) 33.33% of the shares will vest 24 months after April 4, 2025 (the "Issue Date"), (ii) 33.33% of the shares will vest 30 months after the Issue Date, and (iii) 33.34% of the shares will vest 36 months after the Issue Date, subject to the Reporting Person's continuous service through such dates. Read SEC document |
| March 07, 2025 Filed Mar 8, 2025 00:32 UTC | Orchestra BioMed Holdings, Inc. OBIO · Entity 434 | Tax withholdingCommon Stock, par value $0.0001 per share ("Common Stock") | 80,080 | $4.23 | $338,738.40 |
DisclosureSEC source: 0001104659-25-021856 · tm258652-1_4seq1.xml · nonDerivative · entry 1 Hochman David P · CIK 0001292834 · Director · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 499,418 F1 · kind: Represents the withholding of shares by the Issuer to satisfy tax withholding obligations in connection with vesting of restricted stock units. No shares were sold in the market as a result of the vesting of these restricted stock units and the satisfaction of tax withholding obligations. Read SEC document |
| December 23, 2024 Filed Dec 26, 2024 22:46 UTC | Orchestra BioMed Holdings, Inc. OBIO · Entity 434 | PurchaseCommon Stock, par value $0.0001 per share ("Common Stock") | 4,000 | $4.66 | $18,640.00 |
DisclosureSEC source: 0001104659-24-131767 · tm2431687-2_4seq1.xml · nonDerivative · entry 1 Hochman David P · CIK 0001292834 · Director · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 579,498 F1 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.60 to $4.75. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document |
| December 18, 2024 Filed Dec 19, 2024 13:30 UTC | Orchestra BioMed Holdings, Inc. OBIO · Entity 434 | PurchaseCommon Stock, par value $0.0001 per share ("Common Stock") | 5,000 | $4.91 | $24,550.00 |
DisclosureSEC source: 0001104659-24-130007 · tm2431550-1_4seq1.xml · nonDerivative · entry 1 Hochman David P · CIK 0001292834 · Director · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 575,498 F1 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.88 to $4.94. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document |
| September 25, 2024 Filed Sep 26, 2024 12:15 UTC | Orchestra BioMed Holdings, Inc. OBIO · Entity 434 | PurchaseCommon Stock | 2,000 | $4.73 | $9,460.00 |
DisclosureSEC source: 0001104659-24-103002 · tm2425000-1_4seq1.xml · nonDerivative · entry 5 Hochman David P · CIK 0001292834 · Director · See Remarks 10b5-1 filing: No plan indicated Ownership: Indirect · By the Judah Herman Hochman 2019 Trust Disclosed balance after: 2,000 F5 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.72 to $4.77. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the SEC, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document |
| September 25, 2024 Filed Sep 26, 2024 12:15 UTC | Orchestra BioMed Holdings, Inc. OBIO · Entity 434 | PurchaseCommon Stock | 2,000 | $4.70 | $9,400.00 |
DisclosureSEC source: 0001104659-24-103002 · tm2425000-1_4seq1.xml · nonDerivative · entry 4 Hochman David P · CIK 0001292834 · Director · See Remarks 10b5-1 filing: No plan indicated Ownership: Indirect · By the Hannah Hochman 2019 Trust Disclosed balance after: 2,000 F4 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.68 to $4.77. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the SEC, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document |
| September 25, 2024 Filed Sep 26, 2024 12:15 UTC | Orchestra BioMed Holdings, Inc. OBIO · Entity 434 | PurchaseCommon Stock | 2,000 | $4.74 | $9,480.00 |
DisclosureSEC source: 0001104659-24-103002 · tm2425000-1_4seq1.xml · nonDerivative · entry 3 Hochman David P · CIK 0001292834 · Director · See Remarks 10b5-1 filing: No plan indicated Ownership: Indirect · By the Solomon Ascher Hochman 2019 Trust Disclosed balance after: 2,000 F3 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.72 to $4.75. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the SEC, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document |
| September 25, 2024 Filed Sep 26, 2024 12:15 UTC | Orchestra BioMed Holdings, Inc. OBIO · Entity 434 | PurchaseCommon Stock | 1,500 | $4.86 | $7,290.00 |
DisclosureSEC source: 0001104659-24-103002 · tm2425000-1_4seq1.xml · nonDerivative · entry 2 Hochman David P · CIK 0001292834 · Director · See Remarks 10b5-1 filing: No plan indicated Ownership: Indirect · By the DPH 2008 Trust Disclosed balance after: 335,002 F2 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.83 to $4.87, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the SEC, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document |
| September 24, 2024 Filed Sep 26, 2024 12:15 UTC | Orchestra BioMed Holdings, Inc. OBIO · Entity 434 | PurchaseCommon Stock, par value $0.0001 per share ("Common Stock") | 2,500 | $4.91 | $12,275.00 |
DisclosureSEC source: 0001104659-24-103002 · tm2425000-1_4seq1.xml · nonDerivative · entry 1 Hochman David P · CIK 0001292834 · Director · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 570,498 F1 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.90 to $4.95. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission ("SEC"), upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document |
| August 14, 2024 Filed Aug 15, 2024 21:30 UTC | Orchestra BioMed Holdings, Inc. OBIO · Entity 434 | PurchaseCommon Stock, par value $0.0001 per share ("Common Stock") | 2,500 | $5.84 | $14,600.00 |
DisclosureSEC source: 0001104659-24-090181 · tm2421778-1_4seq1.xml · nonDerivative · entry 1 Hochman David P · CIK 0001292834 · Director · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 567,998 Read SEC document |
| June 25, 2024 Filed Jun 26, 2024 20:15 UTC | Orchestra BioMed Holdings, Inc. OBIO · Entity 434 | PurchaseCommon Stock, par value $0.0001 per share ("Common Stock") | 1,000 | $6.95 | $6,950.00 |
DisclosureSEC source: 0001104659-24-075169 · tm2418333-1_4seq1.xml · nonDerivative · entry 1 Hochman David P · CIK 0001292834 · Director · See Remarks 10b5-1 filing: No plan indicated Ownership: Indirect · By the DPH 2008 Trust Disclosed balance after: 333,502 Read SEC document |
| May 17, 2024 Filed May 20, 2024 20:15 UTC | Orchestra BioMed Holdings, Inc. OBIO · Entity 434 | GrantCommon Stock | 3,000 | $5.15 | $15,450.00 |
DisclosureSEC source: 0001104659-24-063414 · tm2414952-1_4seq1.xml · nonDerivative · entry 2 Hochman David P · CIK 0001292834 · Director · See Remarks 10b5-1 filing: No plan indicated Ownership: Indirect · By the DPH 2008 Trust Disclosed balance after: 332,502 F2 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.92 to $5.36, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the SEC, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document |
| May 17, 2024 Filed May 22, 2024 01:15 UTC Amendment | Orchestra BioMed Holdings, Inc. OBIO · Entity 434 | PurchaseCommon Stock | 3,000 | $5.15 | $15,450.00 |
DisclosureSEC source: 0001104659-24-064004 · tm2415131-1_4aseq1.xml · nonDerivative · entry 2 Hochman David P · CIK 0001292834 · Director · See Remarks 10b5-1 filing: No plan indicated Ownership: Indirect · By the DPH 2008 Trust Disclosed balance after: 332,502 F1 · security: On May 20, 2024, the Reporting Person filed a Form 4 which inadvertently misstated the transaction codes in Column 3 of Table I. This amendment is filed solely to correct the transaction codes in Column 3 of Table I to "P". The remainder of the information in the original filing is not restated in this amendment, and no other amendment is made to the original filing. F3 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.92 to $5.36, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the SEC, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document |
| May 16, 2024 Filed May 20, 2024 20:15 UTC | Orchestra BioMed Holdings, Inc. OBIO · Entity 434 | GrantCommon Stock, par value $0.0001 per share ("Common Stock") | 2,000 | $4.75 | $9,500.00 |
DisclosureSEC source: 0001104659-24-063414 · tm2414952-1_4seq1.xml · nonDerivative · entry 1 Hochman David P · CIK 0001292834 · Director · See Remarks 10b5-1 filing: No plan indicated Ownership: Indirect · By the DPH 2008 Trust Disclosed balance after: 329,502 F1 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.74 to $4.78, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document |
| May 16, 2024 Filed May 22, 2024 01:15 UTC Amendment | Orchestra BioMed Holdings, Inc. OBIO · Entity 434 | PurchaseCommon Stock, par value $0.0001 per share ("Common Stock") | 2,000 | $4.75 | $9,500.00 |
DisclosureSEC source: 0001104659-24-064004 · tm2415131-1_4aseq1.xml · nonDerivative · entry 1 Hochman David P · CIK 0001292834 · Director · See Remarks 10b5-1 filing: No plan indicated Ownership: Indirect · By the DPH 2008 Trust Disclosed balance after: 329,502 F1 · security: On May 20, 2024, the Reporting Person filed a Form 4 which inadvertently misstated the transaction codes in Column 3 of Table I. This amendment is filed solely to correct the transaction codes in Column 3 of Table I to "P". The remainder of the information in the original filing is not restated in this amendment, and no other amendment is made to the original filing. F2 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.74 to $4.78, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document |
| May 08, 2024 Filed May 10, 2024 21:22 UTC | Orchestra BioMed Holdings, Inc. OBIO · Entity 434 | GrantCommon Stock | 100,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-060001 · tm2414108-4_4seq1.xml · nonDerivative · entry 2 Hochman David P · CIK 0001292834 · Director · See Remarks 10b5-1 filing: No plan indicated Ownership: Indirect · By the DPH 2008 Trust Disclosed balance after: 327,502 F1 · shares: Represents an award of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of Common Stock. The RSUs vest as follows: (i) 15,000 RSUs will vest on June 10, 2025, and (ii) the remaining 85,000 RSUs will vest in equal installments on September 10, 2025, November 10, 2025, December 10, 2025, June 10, 2026, September 10, 2026, December 10, 2026, March 22, 2027, June 10, 2027, September 10, 2027, December 10, 2027, March 22, 2028 and June 10, 2028, subject to the Reporting Person's continuous service through such dates. Read SEC document |
| May 08, 2024 Filed May 10, 2024 21:22 UTC | Orchestra BioMed Holdings, Inc. OBIO · Entity 434 | GrantCommon Stock, par value $0.0001 per share ("Common Stock") | 100,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-060001 · tm2414108-4_4seq1.xml · nonDerivative · entry 1 Hochman David P · CIK 0001292834 · Director · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 565,498 F1 · shares: Represents an award of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of Common Stock. The RSUs vest as follows: (i) 15,000 RSUs will vest on June 10, 2025, and (ii) the remaining 85,000 RSUs will vest in equal installments on September 10, 2025, November 10, 2025, December 10, 2025, June 10, 2026, September 10, 2026, December 10, 2026, March 22, 2027, June 10, 2027, September 10, 2027, December 10, 2027, March 22, 2028 and June 10, 2028, subject to the Reporting Person's continuous service through such dates. Read SEC document |
| July 20, 2023 Filed Jul 24, 2023 21:13 UTC | Orchestra BioMed Holdings, Inc. OBIO · Entity 434 | GrantStock Option (Right to Buy) · Derivative | 132,000 | $0.00 Strike: $7.42 | $0.00 |
DisclosureSEC source: 0001104659-23-083505 · tm2321855-10_4seq1.xml · derivative · entry 4 Hochman David P · CIK 0001292834 · Director · See Remarks 10b5-1 filing: No plan indicated Ownership: Indirect · By the DPH 2008 Trust Disclosed balance after: 132,000 Underlying: Common Stock · 132,000 shares Expires 2033-07-20 F2 · derivative.exercise_date: The stock options vest over a four-year period as follows: (i) 25% of the underlying shares will vest on the one-year anniversary of the Vesting Commencement Date and (ii) 75% of the underlying shares will vest in equal installments on a quarterly basis on the last day of each quarter, starting on the last day of the first quarter after the first anniversary of the Vesting Commencement Date, or March 31, 2024, subject to the Reporting Person's continuous service through such dates. Read SEC document |
| July 20, 2023 Filed Jul 24, 2023 21:13 UTC | Orchestra BioMed Holdings, Inc. OBIO · Entity 434 | GrantStock Option (Right to Buy) · Derivative | 100,500 | $0.00 Strike: $7.42 | $0.00 |
DisclosureSEC source: 0001104659-23-083505 · tm2321855-10_4seq1.xml · derivative · entry 3 Hochman David P · CIK 0001292834 · Director · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 100,500 Underlying: Common Stock · 100,500 shares Expires 2033-07-20 F2 · derivative.exercise_date: The stock options vest over a four-year period as follows: (i) 25% of the underlying shares will vest on the one-year anniversary of the Vesting Commencement Date and (ii) 75% of the underlying shares will vest in equal installments on a quarterly basis on the last day of each quarter, starting on the last day of the first quarter after the first anniversary of the Vesting Commencement Date, or March 31, 2024, subject to the Reporting Person's continuous service through such dates. Read SEC document |
| July 20, 2023 Filed Jul 24, 2023 21:13 UTC | Orchestra BioMed Holdings, Inc. OBIO · Entity 434 | GrantCommon Stock | 165,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-083505 · tm2321855-10_4seq1.xml · nonDerivative · entry 2 Hochman David P · CIK 0001292834 · Director · See Remarks 10b5-1 filing: No plan indicated Ownership: Indirect · By the DPH 2008 Trust Disclosed balance after: 227,502 F1 · shares: Represents an award of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of Common Stock. The RSUs vest over a three-year period as follows: (i) 34% of the shares will vest on the 18-month anniversary of January 26, 2023 (the "Vesting Commencement Date"), (ii) 33% the shares will vest on the two-year anniversary of the Vesting Commencement Date, and (iii) 33% the shares will vest on the three-year anniversary of the Vesting Commencement Date, subject to the Reporting Person's continuous service through such dates. Read SEC document |
| July 20, 2023 Filed Jul 24, 2023 21:13 UTC | Orchestra BioMed Holdings, Inc. OBIO · Entity 434 | GrantCommon Stock, par value $0.0001 per share ("Common Stock") | 300,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-083505 · tm2321855-10_4seq1.xml · nonDerivative · entry 1 Hochman David P · CIK 0001292834 · Director · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 465,498 F1 · shares: Represents an award of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of Common Stock. The RSUs vest over a three-year period as follows: (i) 34% of the shares will vest on the 18-month anniversary of January 26, 2023 (the "Vesting Commencement Date"), (ii) 33% the shares will vest on the two-year anniversary of the Vesting Commencement Date, and (iii) 33% the shares will vest on the three-year anniversary of the Vesting Commencement Date, subject to the Reporting Person's continuous service through such dates. Read SEC document |
| April 12, 2023 Filed May 5, 2023 23:39 UTC | Orchestra BioMed Holdings, Inc. OBIO · Entity 434 | Exercise / conversionRight to Receive Earnout Shares · Derivative | 683 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001213900-23-037001 · ownership.xml · derivative · entry 6 Hochman David P · CIK 0001292834 · Director · See Remarks 10b5-1 filing: No plan indicated Ownership: Indirect · By the NSH 2008 Family Trust Disclosed balance after: 683 Underlying: Common Stock · 683 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Pursuant to the Agreement and Plan of Merger, dated as of July 4, 2022 (and as subsequently amended) by and among the Issuer and certain other parties named therein (the "Merger Agreement"), the Reporting Person has the contingent right to receive, for no additional consideration, the Reporting Person's Pro Rata Portion (as such term is defined in the Merger Agreement ) of 8,000,000 shares of common stock of the Issuer (the "Earnout Shares") if, at any time from January 26, 2023 until January 26, 2028, the volume-weighted average price of the common stock of the Issuer is greater than or equal to (i) with respect to 4,000,000 Earnout Shares, $15.00 per share over any 20 trading days within any 30-trading day period (the "Initial Milestone Event") and (ii) with respect to 4,000,000 Earnout Shares, $20.00 per share over any 20 trading days within any 30-trading day period. F2 · derivative.exercise_price: The Initial Milestone Event occurred on April 12, 2023 and 29,551 shares of Common Stock, 11,160 shares of Common Stock and 683 shares of Common Stock were issued to David P. Hochman, the DPH 2008 Trust and the NSH 2008 Family Trust, respectively, on April 19, 2023 in accordance with the Merger Agreement. F1 · kind: Pursuant to the Agreement and Plan of Merger, dated as of July 4, 2022 (and as subsequently amended) by and among the Issuer and certain other parties named therein (the "Merger Agreement"), the Reporting Person has the contingent right to receive, for no additional consideration, the Reporting Person's Pro Rata Portion (as such term is defined in the Merger Agreement ) of 8,000,000 shares of common stock of the Issuer (the "Earnout Shares") if, at any time from January 26, 2023 until January 26, 2028, the volume-weighted average price of the common stock of the Issuer is greater than or equal to (i) with respect to 4,000,000 Earnout Shares, $15.00 per share over any 20 trading days within any 30-trading day period (the "Initial Milestone Event") and (ii) with respect to 4,000,000 Earnout Shares, $20.00 per share over any 20 trading days within any 30-trading day period. F2 · kind: The Initial Milestone Event occurred on April 12, 2023 and 29,551 shares of Common Stock, 11,160 shares of Common Stock and 683 shares of Common Stock were issued to David P. Hochman, the DPH 2008 Trust and the NSH 2008 Family Trust, respectively, on April 19, 2023 in accordance with the Merger Agreement. F1 · price: Pursuant to the Agreement and Plan of Merger, dated as of July 4, 2022 (and as subsequently amended) by and among the Issuer and certain other parties named therein (the "Merger Agreement"), the Reporting Person has the contingent right to receive, for no additional consideration, the Reporting Person's Pro Rata Portion (as such term is defined in the Merger Agreement ) of 8,000,000 shares of common stock of the Issuer (the "Earnout Shares") if, at any time from January 26, 2023 until January 26, 2028, the volume-weighted average price of the common stock of the Issuer is greater than or equal to (i) with respect to 4,000,000 Earnout Shares, $15.00 per share over any 20 trading days within any 30-trading day period (the "Initial Milestone Event") and (ii) with respect to 4,000,000 Earnout Shares, $20.00 per share over any 20 trading days within any 30-trading day period. F2 · price: The Initial Milestone Event occurred on April 12, 2023 and 29,551 shares of Common Stock, 11,160 shares of Common Stock and 683 shares of Common Stock were issued to David P. Hochman, the DPH 2008 Trust and the NSH 2008 Family Trust, respectively, on April 19, 2023 in accordance with the Merger Agreement. F1 · derivative.exercise_date: Pursuant to the Agreement and Plan of Merger, dated as of July 4, 2022 (and as subsequently amended) by and among the Issuer and certain other parties named therein (the "Merger Agreement"), the Reporting Person has the contingent right to receive, for no additional consideration, the Reporting Person's Pro Rata Portion (as such term is defined in the Merger Agreement ) of 8,000,000 shares of common stock of the Issuer (the "Earnout Shares") if, at any time from January 26, 2023 until January 26, 2028, the volume-weighted average price of the common stock of the Issuer is greater than or equal to (i) with respect to 4,000,000 Earnout Shares, $15.00 per share over any 20 trading days within any 30-trading day period (the "Initial Milestone Event") and (ii) with respect to 4,000,000 Earnout Shares, $20.00 per share over any 20 trading days within any 30-trading day period. F2 · derivative.exercise_date: The Initial Milestone Event occurred on April 12, 2023 and 29,551 shares of Common Stock, 11,160 shares of Common Stock and 683 shares of Common Stock were issued to David P. Hochman, the DPH 2008 Trust and the NSH 2008 Family Trust, respectively, on April 19, 2023 in accordance with the Merger Agreement. F1 · derivative.expiration_date: Pursuant to the Agreement and Plan of Merger, dated as of July 4, 2022 (and as subsequently amended) by and among the Issuer and certain other parties named therein (the "Merger Agreement"), the Reporting Person has the contingent right to receive, for no additional consideration, the Reporting Person's Pro Rata Portion (as such term is defined in the Merger Agreement ) of 8,000,000 shares of common stock of the Issuer (the "Earnout Shares") if, at any time from January 26, 2023 until January 26, 2028, the volume-weighted average price of the common stock of the Issuer is greater than or equal to (i) with respect to 4,000,000 Earnout Shares, $15.00 per share over any 20 trading days within any 30-trading day period (the "Initial Milestone Event") and (ii) with respect to 4,000,000 Earnout Shares, $20.00 per share over any 20 trading days within any 30-trading day period. F2 · derivative.expiration_date: The Initial Milestone Event occurred on April 12, 2023 and 29,551 shares of Common Stock, 11,160 shares of Common Stock and 683 shares of Common Stock were issued to David P. Hochman, the DPH 2008 Trust and the NSH 2008 Family Trust, respectively, on April 19, 2023 in accordance with the Merger Agreement. Read SEC document |
| April 12, 2023 Filed May 5, 2023 23:39 UTC | Orchestra BioMed Holdings, Inc. OBIO · Entity 434 | Exercise / conversionRight to Receive Earnout Shares · Derivative | 11,160 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001213900-23-037001 · ownership.xml · derivative · entry 5 Hochman David P · CIK 0001292834 · Director · See Remarks 10b5-1 filing: No plan indicated Ownership: Indirect · By the DPH 2008 Trust Disclosed balance after: 11,160 Underlying: Common Stock · 11,160 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Pursuant to the Agreement and Plan of Merger, dated as of July 4, 2022 (and as subsequently amended) by and among the Issuer and certain other parties named therein (the "Merger Agreement"), the Reporting Person has the contingent right to receive, for no additional consideration, the Reporting Person's Pro Rata Portion (as such term is defined in the Merger Agreement ) of 8,000,000 shares of common stock of the Issuer (the "Earnout Shares") if, at any time from January 26, 2023 until January 26, 2028, the volume-weighted average price of the common stock of the Issuer is greater than or equal to (i) with respect to 4,000,000 Earnout Shares, $15.00 per share over any 20 trading days within any 30-trading day period (the "Initial Milestone Event") and (ii) with respect to 4,000,000 Earnout Shares, $20.00 per share over any 20 trading days within any 30-trading day period. F2 · derivative.exercise_price: The Initial Milestone Event occurred on April 12, 2023 and 29,551 shares of Common Stock, 11,160 shares of Common Stock and 683 shares of Common Stock were issued to David P. Hochman, the DPH 2008 Trust and the NSH 2008 Family Trust, respectively, on April 19, 2023 in accordance with the Merger Agreement. F1 · kind: Pursuant to the Agreement and Plan of Merger, dated as of July 4, 2022 (and as subsequently amended) by and among the Issuer and certain other parties named therein (the "Merger Agreement"), the Reporting Person has the contingent right to receive, for no additional consideration, the Reporting Person's Pro Rata Portion (as such term is defined in the Merger Agreement ) of 8,000,000 shares of common stock of the Issuer (the "Earnout Shares") if, at any time from January 26, 2023 until January 26, 2028, the volume-weighted average price of the common stock of the Issuer is greater than or equal to (i) with respect to 4,000,000 Earnout Shares, $15.00 per share over any 20 trading days within any 30-trading day period (the "Initial Milestone Event") and (ii) with respect to 4,000,000 Earnout Shares, $20.00 per share over any 20 trading days within any 30-trading day period. F2 · kind: The Initial Milestone Event occurred on April 12, 2023 and 29,551 shares of Common Stock, 11,160 shares of Common Stock and 683 shares of Common Stock were issued to David P. Hochman, the DPH 2008 Trust and the NSH 2008 Family Trust, respectively, on April 19, 2023 in accordance with the Merger Agreement. F1 · price: Pursuant to the Agreement and Plan of Merger, dated as of July 4, 2022 (and as subsequently amended) by and among the Issuer and certain other parties named therein (the "Merger Agreement"), the Reporting Person has the contingent right to receive, for no additional consideration, the Reporting Person's Pro Rata Portion (as such term is defined in the Merger Agreement ) of 8,000,000 shares of common stock of the Issuer (the "Earnout Shares") if, at any time from January 26, 2023 until January 26, 2028, the volume-weighted average price of the common stock of the Issuer is greater than or equal to (i) with respect to 4,000,000 Earnout Shares, $15.00 per share over any 20 trading days within any 30-trading day period (the "Initial Milestone Event") and (ii) with respect to 4,000,000 Earnout Shares, $20.00 per share over any 20 trading days within any 30-trading day period. F2 · price: The Initial Milestone Event occurred on April 12, 2023 and 29,551 shares of Common Stock, 11,160 shares of Common Stock and 683 shares of Common Stock were issued to David P. Hochman, the DPH 2008 Trust and the NSH 2008 Family Trust, respectively, on April 19, 2023 in accordance with the Merger Agreement. F1 · derivative.exercise_date: Pursuant to the Agreement and Plan of Merger, dated as of July 4, 2022 (and as subsequently amended) by and among the Issuer and certain other parties named therein (the "Merger Agreement"), the Reporting Person has the contingent right to receive, for no additional consideration, the Reporting Person's Pro Rata Portion (as such term is defined in the Merger Agreement ) of 8,000,000 shares of common stock of the Issuer (the "Earnout Shares") if, at any time from January 26, 2023 until January 26, 2028, the volume-weighted average price of the common stock of the Issuer is greater than or equal to (i) with respect to 4,000,000 Earnout Shares, $15.00 per share over any 20 trading days within any 30-trading day period (the "Initial Milestone Event") and (ii) with respect to 4,000,000 Earnout Shares, $20.00 per share over any 20 trading days within any 30-trading day period. F2 · derivative.exercise_date: The Initial Milestone Event occurred on April 12, 2023 and 29,551 shares of Common Stock, 11,160 shares of Common Stock and 683 shares of Common Stock were issued to David P. Hochman, the DPH 2008 Trust and the NSH 2008 Family Trust, respectively, on April 19, 2023 in accordance with the Merger Agreement. F1 · derivative.expiration_date: Pursuant to the Agreement and Plan of Merger, dated as of July 4, 2022 (and as subsequently amended) by and among the Issuer and certain other parties named therein (the "Merger Agreement"), the Reporting Person has the contingent right to receive, for no additional consideration, the Reporting Person's Pro Rata Portion (as such term is defined in the Merger Agreement ) of 8,000,000 shares of common stock of the Issuer (the "Earnout Shares") if, at any time from January 26, 2023 until January 26, 2028, the volume-weighted average price of the common stock of the Issuer is greater than or equal to (i) with respect to 4,000,000 Earnout Shares, $15.00 per share over any 20 trading days within any 30-trading day period (the "Initial Milestone Event") and (ii) with respect to 4,000,000 Earnout Shares, $20.00 per share over any 20 trading days within any 30-trading day period. F2 · derivative.expiration_date: The Initial Milestone Event occurred on April 12, 2023 and 29,551 shares of Common Stock, 11,160 shares of Common Stock and 683 shares of Common Stock were issued to David P. Hochman, the DPH 2008 Trust and the NSH 2008 Family Trust, respectively, on April 19, 2023 in accordance with the Merger Agreement. Read SEC document |
| April 12, 2023 Filed May 5, 2023 23:39 UTC | Orchestra BioMed Holdings, Inc. OBIO · Entity 434 | Exercise / conversionRight to Receive Earnout Shares · Derivative | 29,551 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001213900-23-037001 · ownership.xml · derivative · entry 4 Hochman David P · CIK 0001292834 · Director · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 29,551 Underlying: Common Stock · 29,551 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Pursuant to the Agreement and Plan of Merger, dated as of July 4, 2022 (and as subsequently amended) by and among the Issuer and certain other parties named therein (the "Merger Agreement"), the Reporting Person has the contingent right to receive, for no additional consideration, the Reporting Person's Pro Rata Portion (as such term is defined in the Merger Agreement ) of 8,000,000 shares of common stock of the Issuer (the "Earnout Shares") if, at any time from January 26, 2023 until January 26, 2028, the volume-weighted average price of the common stock of the Issuer is greater than or equal to (i) with respect to 4,000,000 Earnout Shares, $15.00 per share over any 20 trading days within any 30-trading day period (the "Initial Milestone Event") and (ii) with respect to 4,000,000 Earnout Shares, $20.00 per share over any 20 trading days within any 30-trading day period. F2 · derivative.exercise_price: The Initial Milestone Event occurred on April 12, 2023 and 29,551 shares of Common Stock, 11,160 shares of Common Stock and 683 shares of Common Stock were issued to David P. Hochman, the DPH 2008 Trust and the NSH 2008 Family Trust, respectively, on April 19, 2023 in accordance with the Merger Agreement. F1 · kind: Pursuant to the Agreement and Plan of Merger, dated as of July 4, 2022 (and as subsequently amended) by and among the Issuer and certain other parties named therein (the "Merger Agreement"), the Reporting Person has the contingent right to receive, for no additional consideration, the Reporting Person's Pro Rata Portion (as such term is defined in the Merger Agreement ) of 8,000,000 shares of common stock of the Issuer (the "Earnout Shares") if, at any time from January 26, 2023 until January 26, 2028, the volume-weighted average price of the common stock of the Issuer is greater than or equal to (i) with respect to 4,000,000 Earnout Shares, $15.00 per share over any 20 trading days within any 30-trading day period (the "Initial Milestone Event") and (ii) with respect to 4,000,000 Earnout Shares, $20.00 per share over any 20 trading days within any 30-trading day period. F2 · kind: The Initial Milestone Event occurred on April 12, 2023 and 29,551 shares of Common Stock, 11,160 shares of Common Stock and 683 shares of Common Stock were issued to David P. Hochman, the DPH 2008 Trust and the NSH 2008 Family Trust, respectively, on April 19, 2023 in accordance with the Merger Agreement. F1 · price: Pursuant to the Agreement and Plan of Merger, dated as of July 4, 2022 (and as subsequently amended) by and among the Issuer and certain other parties named therein (the "Merger Agreement"), the Reporting Person has the contingent right to receive, for no additional consideration, the Reporting Person's Pro Rata Portion (as such term is defined in the Merger Agreement ) of 8,000,000 shares of common stock of the Issuer (the "Earnout Shares") if, at any time from January 26, 2023 until January 26, 2028, the volume-weighted average price of the common stock of the Issuer is greater than or equal to (i) with respect to 4,000,000 Earnout Shares, $15.00 per share over any 20 trading days within any 30-trading day period (the "Initial Milestone Event") and (ii) with respect to 4,000,000 Earnout Shares, $20.00 per share over any 20 trading days within any 30-trading day period. F2 · price: The Initial Milestone Event occurred on April 12, 2023 and 29,551 shares of Common Stock, 11,160 shares of Common Stock and 683 shares of Common Stock were issued to David P. Hochman, the DPH 2008 Trust and the NSH 2008 Family Trust, respectively, on April 19, 2023 in accordance with the Merger Agreement. F1 · derivative.exercise_date: Pursuant to the Agreement and Plan of Merger, dated as of July 4, 2022 (and as subsequently amended) by and among the Issuer and certain other parties named therein (the "Merger Agreement"), the Reporting Person has the contingent right to receive, for no additional consideration, the Reporting Person's Pro Rata Portion (as such term is defined in the Merger Agreement ) of 8,000,000 shares of common stock of the Issuer (the "Earnout Shares") if, at any time from January 26, 2023 until January 26, 2028, the volume-weighted average price of the common stock of the Issuer is greater than or equal to (i) with respect to 4,000,000 Earnout Shares, $15.00 per share over any 20 trading days within any 30-trading day period (the "Initial Milestone Event") and (ii) with respect to 4,000,000 Earnout Shares, $20.00 per share over any 20 trading days within any 30-trading day period. F2 · derivative.exercise_date: The Initial Milestone Event occurred on April 12, 2023 and 29,551 shares of Common Stock, 11,160 shares of Common Stock and 683 shares of Common Stock were issued to David P. Hochman, the DPH 2008 Trust and the NSH 2008 Family Trust, respectively, on April 19, 2023 in accordance with the Merger Agreement. F1 · derivative.expiration_date: Pursuant to the Agreement and Plan of Merger, dated as of July 4, 2022 (and as subsequently amended) by and among the Issuer and certain other parties named therein (the "Merger Agreement"), the Reporting Person has the contingent right to receive, for no additional consideration, the Reporting Person's Pro Rata Portion (as such term is defined in the Merger Agreement ) of 8,000,000 shares of common stock of the Issuer (the "Earnout Shares") if, at any time from January 26, 2023 until January 26, 2028, the volume-weighted average price of the common stock of the Issuer is greater than or equal to (i) with respect to 4,000,000 Earnout Shares, $15.00 per share over any 20 trading days within any 30-trading day period (the "Initial Milestone Event") and (ii) with respect to 4,000,000 Earnout Shares, $20.00 per share over any 20 trading days within any 30-trading day period. F2 · derivative.expiration_date: The Initial Milestone Event occurred on April 12, 2023 and 29,551 shares of Common Stock, 11,160 shares of Common Stock and 683 shares of Common Stock were issued to David P. Hochman, the DPH 2008 Trust and the NSH 2008 Family Trust, respectively, on April 19, 2023 in accordance with the Merger Agreement. Read SEC document |
| April 12, 2023 Filed May 5, 2023 23:39 UTC | Orchestra BioMed Holdings, Inc. OBIO · Entity 434 | Exercise / conversionCommon Stock | 683 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001213900-23-037001 · ownership.xml · nonDerivative · entry 3 Hochman David P · CIK 0001292834 · Director · See Remarks 10b5-1 filing: No plan indicated Ownership: Indirect · By the NSH 2008 Family Trust Disclosed balance after: 3,823 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Pursuant to the Agreement and Plan of Merger, dated as of July 4, 2022 (and as subsequently amended) by and among the Issuer and certain other parties named therein (the "Merger Agreement"), the Reporting Person has the contingent right to receive, for no additional consideration, the Reporting Person's Pro Rata Portion (as such term is defined in the Merger Agreement ) of 8,000,000 shares of common stock of the Issuer (the "Earnout Shares") if, at any time from January 26, 2023 until January 26, 2028, the volume-weighted average price of the common stock of the Issuer is greater than or equal to (i) with respect to 4,000,000 Earnout Shares, $15.00 per share over any 20 trading days within any 30-trading day period (the "Initial Milestone Event") and (ii) with respect to 4,000,000 Earnout Shares, $20.00 per share over any 20 trading days within any 30-trading day period. F2 · kind: The Initial Milestone Event occurred on April 12, 2023 and 29,551 shares of Common Stock, 11,160 shares of Common Stock and 683 shares of Common Stock were issued to David P. Hochman, the DPH 2008 Trust and the NSH 2008 Family Trust, respectively, on April 19, 2023 in accordance with the Merger Agreement. F1 · price: Pursuant to the Agreement and Plan of Merger, dated as of July 4, 2022 (and as subsequently amended) by and among the Issuer and certain other parties named therein (the "Merger Agreement"), the Reporting Person has the contingent right to receive, for no additional consideration, the Reporting Person's Pro Rata Portion (as such term is defined in the Merger Agreement ) of 8,000,000 shares of common stock of the Issuer (the "Earnout Shares") if, at any time from January 26, 2023 until January 26, 2028, the volume-weighted average price of the common stock of the Issuer is greater than or equal to (i) with respect to 4,000,000 Earnout Shares, $15.00 per share over any 20 trading days within any 30-trading day period (the "Initial Milestone Event") and (ii) with respect to 4,000,000 Earnout Shares, $20.00 per share over any 20 trading days within any 30-trading day period. F2 · price: The Initial Milestone Event occurred on April 12, 2023 and 29,551 shares of Common Stock, 11,160 shares of Common Stock and 683 shares of Common Stock were issued to David P. Hochman, the DPH 2008 Trust and the NSH 2008 Family Trust, respectively, on April 19, 2023 in accordance with the Merger Agreement. Read SEC document |
| April 12, 2023 Filed May 5, 2023 23:39 UTC | Orchestra BioMed Holdings, Inc. OBIO · Entity 434 | Exercise / conversionCommon Stock | 11,160 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001213900-23-037001 · ownership.xml · nonDerivative · entry 2 Hochman David P · CIK 0001292834 · Director · See Remarks 10b5-1 filing: No plan indicated Ownership: Indirect · By the DPH 2008 Trust Disclosed balance after: 62,502 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Pursuant to the Agreement and Plan of Merger, dated as of July 4, 2022 (and as subsequently amended) by and among the Issuer and certain other parties named therein (the "Merger Agreement"), the Reporting Person has the contingent right to receive, for no additional consideration, the Reporting Person's Pro Rata Portion (as such term is defined in the Merger Agreement ) of 8,000,000 shares of common stock of the Issuer (the "Earnout Shares") if, at any time from January 26, 2023 until January 26, 2028, the volume-weighted average price of the common stock of the Issuer is greater than or equal to (i) with respect to 4,000,000 Earnout Shares, $15.00 per share over any 20 trading days within any 30-trading day period (the "Initial Milestone Event") and (ii) with respect to 4,000,000 Earnout Shares, $20.00 per share over any 20 trading days within any 30-trading day period. F2 · kind: The Initial Milestone Event occurred on April 12, 2023 and 29,551 shares of Common Stock, 11,160 shares of Common Stock and 683 shares of Common Stock were issued to David P. Hochman, the DPH 2008 Trust and the NSH 2008 Family Trust, respectively, on April 19, 2023 in accordance with the Merger Agreement. F1 · price: Pursuant to the Agreement and Plan of Merger, dated as of July 4, 2022 (and as subsequently amended) by and among the Issuer and certain other parties named therein (the "Merger Agreement"), the Reporting Person has the contingent right to receive, for no additional consideration, the Reporting Person's Pro Rata Portion (as such term is defined in the Merger Agreement ) of 8,000,000 shares of common stock of the Issuer (the "Earnout Shares") if, at any time from January 26, 2023 until January 26, 2028, the volume-weighted average price of the common stock of the Issuer is greater than or equal to (i) with respect to 4,000,000 Earnout Shares, $15.00 per share over any 20 trading days within any 30-trading day period (the "Initial Milestone Event") and (ii) with respect to 4,000,000 Earnout Shares, $20.00 per share over any 20 trading days within any 30-trading day period. F2 · price: The Initial Milestone Event occurred on April 12, 2023 and 29,551 shares of Common Stock, 11,160 shares of Common Stock and 683 shares of Common Stock were issued to David P. Hochman, the DPH 2008 Trust and the NSH 2008 Family Trust, respectively, on April 19, 2023 in accordance with the Merger Agreement. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.